| 
             
			
			 "We looked at potential deals but found the asking prices to be too 
			high for the businesses," said Sanofi Chairman Serge Weinberg. 
			 
			"We have opted for a balanced a strategy of innovation and 
			diversification that makes acquisitions not indispensable." 
			 
			The global pharmaceutical industry has been consolidating in recent 
			years as companies seek to replace drugs that are losing patent 
			protection and renew their pipeline with new products. 
			 
			Through early March, M&A transactions targeting biotech and pharma 
			companies reached $59.3 billion this year, a 94 percent increase 
			over the same period a year ago and the highest volume for this 
			stage in any year since 2009. 
			 
			(Reporting by Leila Abboud; Editing by Miral Fahmy) 
			[© 2015 Thomson Reuters. All rights 
				reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  |